'Do not approve Vioxx successor'
A painkiller proposed as a successor to Vioxx should not be approved, a panel of federal health advisers overwhelmingly recommended.
By Agencies |
WASHINGTON: A painkiller proposed as a successor to Vioxx should not be approved, a panel of federal health advisers overwhelmingly recommended.
The nonbinding 20-1 vote was on the prescription drug Arcoxia, made by Merck & Co, Inc.
A US Food and Drug Administration drug safety expert had told the panel yesterday the drug may increase substantially the risk of stroke and heart attack and is no more effective for pain relief than other medicines in the same class.
"What you're talking about is a potential public health disaster," Dr David Graham told the outside experts before the vote. Graham was a leading critic of Vioxx, a related drug also known as rofecoxib.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
